Lisdexamphetamine versus methylphenidate for paediatric patients with attention-deficit hyperactivity disorder and type 1 diabetes (LAMAinDiab): protocol for a multicentre, randomised cross-over clinical trial in an outpatient telemedicine-supported setting

Lisdexamphetamine versus methylphenidate for paediatric patients with attention-deficit hyperactivity disorder and type 1 diabetes (LAMAinDiab): protocol for a multicentre, randomised cross-over clinical trial in an outpatient telemedicine-supported setting

Introduction Attention deficit hyperactivity disorder (ADHD) affects 5%–10% of paediatric population and is reportedly more common in children with type 1 diabetes (T1D), exacerbating its clinical course. Proper treatment of ADHD in such patients may thus provide neurological and metabolic benefits....

Full description

Saved in:
Bibliographic Details
Main Authors: Przemysława Jarosz-Chobot, Agnieszka Szadkowska, Małgorzata Myśliwiec, Wojciech Fendler, Agnieszka Butwicka, Arkadiusz Michalak, Jędrzej Chrzanowski, Hanna Kuśmierczyk-Kozieł, Ewa Klejman, Katarzyna Błaziak, Beata Mianowska, Agata P Chobot, Iwona Makowska, Anna Kalenik, Monika Zamarlik, Tomasz Wolańczyk
Format: Article
Language:English
Published: BMJ Publishing Group 2023-12-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/13/12/e078112.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://bmjopen.bmj.com/content/13/12/e078112.full

Similar Items